C. Robertson

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Cary N. Robertson, C Robertson, C. N. Robertson, Cary N Robertson, C.n. Robertson, Cary Robertson, C N Robertson
Publication record
178 papers · 9,470 citations · H-index 42

PAPERS

Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement.
202327 citationsauthor #37
MP73-13 MRI ANALYSIS OF PROSTATE MORPHOMETRY AND PERIPROSTATIC ANATOMICAL RELATIONSHIPS BEFORE AND AFTER PARTIAL HIGH-INTENSITY FOCUSED ULTRASOUND TREATMENT OF LOCALIZED PROSTATE CANCER.
20230 citationsauthor #5
Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society.
202112 citationsauthor #11
Immunomodulatory lipid mediator profiling of cerebrospinal fluid following surgery in older adults
20216 citationsauthor #47
TITLE: Cerebrospinal Fluid Proteome Changes in Older Non-Cardiac Surgical Patients with Postoperative Cognitive Dysfunction RUNNING TITLE: Cerebrospinal Fluid Proteome Changes after Surgery AUTHORS:
20210 citationsauthor #52
Available evidence on HIFU for focal treatment of prostate cancer: a systematic review
202145 citationsauthor #4
Immunomodulatory lipid mediator profiling of cerebrospinal fluid following surgery in older adults
20210 citationsauthor #47
A protocol to reduce self-reported pain scores and adverse events following lumbar punctures in older adults
202020 citationsauthor #81
Illness uncertainty, partner support, and quality of life: A dyadic longitudinal investigation of couples facing prostate cancer
201931 citationsauthor #5
Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.
201924 citationsauthor #4
Prostate Cancer Treatment Options for Men with Significant Urinary Symptoms and Enlarged Prostates
20180 citationsauthor #1
High-intensity focused ultrasound for focal therapy: reality or pitfall?
201716 citationsauthor #3
Salvage high‐intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi‐institutional analysis of 418 patients
201780 citationsauthor #11
Kidney Cancer
201642 citationsauthor #22
Effects of physical and mental health on relationship satisfaction: a dyadic, longitudinal examination of couples facing prostate cancer
201630 citationsauthor #4
Prostate Cancer Knowledge Scale
20150 citationsauthor #6
MP14-13 WEIGHING IN ON ACTIVE SURVEILLANCE: IMPACT OF OBESITY ON PATIENT COUNSELING
20150 citationsauthor #6
United States experience with primary HIFU therapy for patients with low-risk prostate cancer: results of the Enlight trial
20153 citationsauthor #1
MP46-11 HIGH INTENSITY FOCUSED ULTRASOUND IN PROSTATE CANCER. MULTICENTRIC, LONG TERM RETREATMENT RATE DECREASE
20140 citationsauthor #11
The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel
201498 citationsauthor #10
Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?
201411 citationsauthor #5
Patient-Provider Communication Scale
20140 citationsauthor #7
Low central venous pressure versus acute normovolemic hemodilution versus conventional fluid management for reducing blood loss in radical retropubic prostatectomy: a randomized controlled trial
20143 citationsauthor #4
Psychosocial trajectories of men monitoring prostate-specific antigen levels following surgery for prostate cancer.
20148 citationsauthor #4
1206 BIOCHEMICAL SURVIVAL AND MORBIDITY OF HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) AS A PRIMARY MONOTHERAPY FOR LOW-RISK LOCALIZED PROSTATE CANCER: OUTCOMES FROM THE @–REGISTRY FOLLOWING THE ENLIGHT TRIAL INCLUSION CRITERIA
20130 citationsauthor #2
1205 AGE STRATIFIED OUTCOMES AFTER PRIMARY HIFU FOR ORGAN LOCALIZED PROSTATE CANCER IN THE SERIE OF 5206 PATIENTS
20131 citationsauthor #9
Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer.
201320 citationsauthor #9
Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center.
201225 citationsauthor #3
African American race to predict for earlier failure of active surveillance: Results from the Duke Prostate Center.
20120 citationsauthor #5
982 Multicentric oncologic outcomes of salvage HIFU for local failure after external beam radio therapy: 7 years biochemical survival of 929 patients
20123 citationsauthor #7
Radical prostatectomy vs radiation therapy and androgen‐suppression therapy in high‐risk prostate cancer
201249 citationsauthor #4
979 Localized prostate cancer control with primary HIFU therapy: Outcomes from 5663 men followed with the @-registry
20121 citationsauthor #9
Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database.
20120 citationsauthor #5
Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database.
20120 citationsauthor #5
2237 DOES LONG-TERM ASPIRIN USE LOWER SERUM PSA LEVELS? - RESULTS FROM THE DUKE PROSTATE CENTER
20121 citationsauthor #6
M-HIFU Inhibits Tumor Growth, Suppresses STAT3 Activity and Enhances Tumor Specific Immunity in a Transplant Tumor Model of Prostate Cancer
201261 citationsauthor #6
Biochemical survival and morbidity of high-intensity focused ultrasound (HIFU) as a primary monotherapy for low-risk localized prostate cancer: Outcomes from the @-registry following the ENLIGHT trial inclusion criteria.
20120 citationsauthor #1
Testicular cancer.
201244 citationsauthor #18
NCCN Kidney Cancer Clinical Practice Guidelines in Oncology
20110 citationsauthor #22
Correlation of prostate‐specific antigen nadir and biochemical failure after high‐intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria – analysis from the @‐Registry
201140 citationsauthor #2
335 DIABETES MELLITUS AND THE RISK OF HIGH-GRADE PROSTATE CANCER: RESULTS FROM THE DUKE PROSTATE CENTER
20111 citationsauthor #7
Prostate cancer and biologies
20110 citationsauthor #1
The Number of High-Risk Factors and the Risk of Prostate Cancer-Specific Mortality Following Radical Prostatectomy or Brachytherapy
20110 citationsauthor #6
Salvage radiation in men after prostate‐specific antigen failure and the risk of death
2011119 citationsauthor #7
1004 10 YEAR OUTCOME AND MORBIDITY OF HIGH-INTENSITY FOCUSSED ULTRASOUND (HIFU) AS A PRIMARY THERAPY FOR LOCALIZED PROSTATE CANCER: OUTCOMES FROM 2552 MEN FOLLOWED WITH THE @-REGISTRY
20112 citationsauthor #10
MP18-15 EFFICACY OF HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) AS A PRIMARY MONOTHERAPY FOR LOW RISK LOCALIZED PROSTATE CANCER: OUTCOMES FROM THE ENLIGHT TRIAL
20111 citationsauthor #1
PSYCHOSOCIAL TRAJECTORIES OF MEN UNDERGOING ACTIVE SURVEILLANCE FOR PROSTATE CANCER
20112 citationsauthor #6
Neoadjuvant Radiotherapy plus Prostatectomy for High Risk Prostate Cancer
20110 citationsauthor #7
HIFU as a Neoadjuvant Therapy in Cancer Treatment
20114 citationsauthor #8
224 BIOCHEMICAL SURVIVAL OF 596 PATIENTS TREATED WITH SALVAGE HIFU AFTER FAILED EXTERNAL BEAM RADIATION TRACKED WITH THE @-REGISTRY AND STRATIFIED BY PSA AND PRE TREATMENT HORMONE USAGE
20110 citationsauthor #7
Prostate‐specific antigen velocity based risk‐adapted discontinuation of prostate cancer screening in elderly men
20117 citationsauthor #4
Abstract 2767: Genetic variation in obesity-related genes ADBR2, ADBR3, GHRL, HSD11B1, and SHC1 and risk of prostate cancer: A VA case-control study
20110 citationsauthor #11
Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy.
201128 citationsauthor #8
3D Conformal and Intensity Modulated Radiotherapy to the Prostate Bed have Similar Biochemical Outcomes
20110 citationsauthor #7
1613 GENETIC VARIATION IN OBESITY-RELATED GENES ADBR2, ADBR3, GHRL, HSD11B1, AND SHC1 AND RISK OF PROSTATE CANCER: A VA CASE-CONTROL STUDY
20110 citationsauthor #11
1204 HEIGHT AND THE RISK FOR AGGRESSIVE PROSTATE CANCER AT THE TIME OF BIOPSY–RESULTS FROM THE DUKE PROSTATE CENTER DATABASE
20110 citationsauthor #5
605 COMBINATION OF ADH GENE POLYMORPHISM AND ALCOHOL CONSUMPTION CONSTITUTES A NOVEL PROSTATE CANCER RISK FACTOR IN AFRICAN-AMERICAN MEN
20110 citationsauthor #9
Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence?
201035 citationsauthor #6
Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.
201024 citationsauthor #4
1724 INITIAL PSA >= 1.5 NG/ML IN MEN =< 50 YEARS OLD PREDICTS A SUBSEQUENT HIGHER RISK OF PROSTATE CANCER
20101 citationsauthor #4
463 HIFU FOLLOWING FAILED RADIATION THERPAY: BIOCHEMICAL SURVIVAL OF ABLATHERM REGISTRY
20100 citationsauthor #10
462 CORRELATION OF DIFFERENT PSA-NADIR CUT OFFS AND BIOCHEMICAL FAILURE AFTER HIGH-INTENSITY FOCUSSED ULTRASOUND (HIFU) OF PROSTATE CANCER BASED ON THE STUTTGART FAILURE CRITERIA – ANALYSIS FROM THE @-REGISTRY
20101 citationsauthor #7
Impact of postoperative prostate‐specific antigen disease recurrence and the use of salvage therapy on the risk of death
201043 citationsauthor #7
Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death
201041 citationsauthor #6
942 TOTAL HIFU AS A PRIMARY THERAPY FOR LOCALISED PROSTATE CANCER: OUTCOMES FROM THE @-REGISTRY DATABASE
20100 citationsauthor #2
Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men.
201011 citationsauthor #4
Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate.
201015 citationsauthor #6
941 CORRELATION OF PSA-NADIR AND BIOCHEMICAL FAILURE AFTER HIGH-INTENSITY FOCUSSED ULTRASOUND (HIFU) OF LOCALIZED PROSTATE CANCER BASED ON THE STUTTGART FAILURE CRITERIA-ANALYSIS FROM THE @-REGISTRY
20100 citationsauthor #7
Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75.
201011 citationsauthor #3
663 ADJUVANT VERSUS SALVAGE RADIATION THERAPY FOR PROSTATE CANCER AND THE RISK OF DEATH
20100 citationsauthor #6
Predicting occult multifocality of renal cell carcinoma.
201029 citationsauthor #7
1839 RISK STRATIFICATION FOR PROSTATE CANCER USING AGE-SPECIFIC PSA QUARTILES
20100 citationsauthor #5
Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy.
200910 citationsauthor #10
WHO DOES NOT NEED FOLLOW UP TWO YEARS AFTER PROSTATECTOMY? AN ANALYSIS OF 1739 PATIENTS AT DUKE UNIVERSITY MEDICAL CENTER
20090 citationsauthor #5
NCCN clinical practice guidelines in oncology: kidney cancer.
2009490 citationsauthor #22
NCCN clinical practice guidelines in oncology: testicular cancer.
2009207 citationsauthor #22
Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?
200942 citationsauthor #9
POD-06.07: Rationale for a Less Aggressive Therapy for Small Renal Tumors
20090 citationsauthor #6
PERINEAL RADICAL PROSTATECTOMY: WHAT ARE THE TEN YEAR OUTCOMES?
20090 citationsauthor #10
PREDICTING NON-ORGAN CONFINED PROSTATE CANCER AFTER THE YEAR 2000
20090 citationsauthor #4
Factors predicting prostatic biopsy Gleason sum under grading.
200925 citationsauthor #7
Prostate-specific antigen screening and prostate cancer mortality: implications of a randomized European study
20091 citationsauthor #3
PHASE I TRIAL OF PROSTATECTOMY AFTER PLANNED PRE-OPERATIVE RADIOTHERAPY FOR HIGH RISK LOCALIZED PROSTATE CANCER: PRELIMINARY RESULTS
20090 citationsauthor #6
High‐intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure
2009146 citationsauthor #11
DELAYED PSA RECURRENCE AFTER RADICAL PROSTATECTOMY: HOW TO IDENTIFY PATIENTS AT RISK AND THEIR CLINICAL OUTCOMES?
20090 citationsauthor #10
CORRELATION OF BIOCHEMICAL EVENTS AND CLINICAL FAILURE FOLLOWING HIGH INTENSITY FOCUSED ULTRASOUND OF THE PROSTATE: THE STUTTGART DEFINTION
20090 citationsauthor #11
A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy.
200971 citationsauthor #6
849 DEFINING BIOCHEMICAL FAILURE FOLLOWING HIGH INTENSITY FOCUSED ULTRASOUND OF THE PROSTATE: THE STUTTGART DEFINITION
20092 citationsauthor #10
SAY NO TO THE US PREVENTATIVE TASK FORCE RECOMMENDATION TO NO LONGER OFFER PROSTATE CANCER SCREENING AFTER AGE 75
20092 citationsauthor #4
PRIMARY PROSTATE HIFU WITHOUT PRETREATMENT HORMONE THERAPY: BIOCHEMICAL SURVIVAL OF 468 PATIENTS TRACKED WITH THE @-REGISTRY
20095 citationsauthor #10
The NCCN Kidney Cancer Clinical Practice Guidelines in OncologyTM
20090 citationsauthor #22
Tumor volume, tumor percentage involvement or prostate volume: Which is predictive of PSA recurrence?
20092 citationsauthor #7
PROSTATE-SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY AND THE RISK OF DEATH
20090 citationsauthor #5
850 PRIMARY PROSTATE HIFU WITHOUT PRETREATMENT HORMONE THERAPY: BIOCHEMICAL SURVIVAL OF 763 PATIENTS TRACKED WITH THE @-REGISTRY
20091 citationsauthor #10
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
2009109 citationsauthor #3
PRE-TREATMENT FACTORS PREDICTIVE OF POSITIVE SURGICAL MARGIN IN CONTEMPORARY RADICAL PROSTATECTOMIES
20081 citationsauthor #7
Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.
200837 citationsauthor #3
Prostate Cancer Satisfaction and Regret after Open Retropubic or Robot-Assisted Laparoscopic Radical Prostatectomy
20081 citationsauthor #7
OLDER MEN ASSOCIATED WITH ADVANCED DISEASE AND POOR OUTCOME: AN ANALYSIS OF 14601 PROSTATE CANCER MEN IN DUKE PROSTATE CENTER
20082 citationsauthor #3
Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen.
200862 citationsauthor #4

TIMELINE

1985 87 citations

1986 35 citations

1987 2,838 citations

1988 92 citations

1989 24 citations

1990 98 citations

1991 19 citations

1992 74 citations

1993 814 citations

1994 17 citations

1995 180 citations

1996 18 citations

1997 291 citations

1998 196 citations

1999 70 citations

2000 49 citations

2001 611 citations

2002 457 citations

2003 83 citations

2004 112 citations

2005 126 citations

2006 16 citations

2007 309 citations

2008 663 citations

2009 1,113 citations

2010 211 citations

2011 204 citations

2012 184 citations

2013 21 citations

2014 120 citations

2015 3 citations

2016 72 citations

2017 96 citations

2018 0 citations

2019 55 citations

2020 20 citations

2021 63 citations

2023 27 citations

Unknown 0 citations

C. Robertson

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT